• CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
  • CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
  • CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
  • CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
  • CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
  • CAS 229614-55-5 Peramivir Pharmaceutical Raw Material

CAS 229614-55-5 Peramivir Pharmaceutical Raw Material

CAS No.: 330600-85-6
Formula: C15h28n4o4
EINECS: /
Type: Pharmaceutical Intermediates
Appearance: Powder
Quality: Technical
Samples:
US$ 350/kg 1 kg(Min.Order)
| Request Sample
Customization:
Trading Company

360° Virtual Tour

Diamond Member Since 2024

Suppliers with verified business licenses

Shaanxi, China
Importers and Exporters
The supplier has import and export rights
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Fast Delivery
The supplier can deliver the goods within 15 days
Low MOQ
The MOQ for the supplier's products is 1
to see all verified strength labels (7)

Basic Info.

Model NO.
HB-Peramivir
Colour
White
Test
HPLC
Packing
Rum, Aluminum Foil Bag
MOQ
1kg
Grade
Food
Shelf Life
2 Years
Storage
Cool Dry Place
Transport Package
Carton Box
Specification
99%
Trademark
Haibo
Origin
Shaanxi, China
HS Code
00000000
Production Capacity
5000000/Year

Product Description

CAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw Material
Product name  Peramivir
CAS NO 330600-85-6
MOQ 1KG
Purity  NLT 98%
Appearance  White powder 
Melting point  170-172ºC
Boiling point  1.39
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
CAS 229614-55-5 Peramivir Pharmaceutical Raw Material



CAS 229614-55-5 Peramivir Pharmaceutical Raw Material
Items
Specifications
Results
Appearance
White Powder
Confirm
Odor& Taste
Characteristic
Confirm
Loss on drying
≤8.0%
2.8%
Assay(HPLC)
99.0% min
99.2%
Ash
≤1.0%
0.35%
Heavy Metal
≤10 ppm
Confirm
As
≤1.0ppm
Confirm
Pb
≤1.0ppm
Confirm
Cd
≤1.0ppm
Confirm
Hg
≤0.1ppm
Confirm
Total plate count
≤1000 cfu/g
Confirms
Yeast&Mold
≤100 cfu/g
Confirms
E.Coli
Negative
Negative
Salmonella
Negative
Negative
Staphylococcus aureus
Negative
Negative
     
CAS 229614-55-5 Peramivir Pharmaceutical Raw Material

CAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw Material
CAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw Material
CAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw Material
CAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw MaterialCAS 229614-55-5 Peramivir Pharmaceutical Raw Material

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2024

Suppliers with verified business licenses

Trading Company
Number of Employees
28
Year of Establishment
2020-08-05